Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16253039 | 0.81 | KDM4E (0.48) | ALDH1A1KDM4ECYP3A4CYP2C19HPGD | |
| SCHEMBL3708233 | 0.81 | KDM4E (0.47) | ALDH1A1KDM4EHPGDLMNA | |
| SCHEMBL16238311 | 0.81 | KDM4E (0.47) | ALDH1A1KDM4EHPGDLMNA | |
| SCHEMBL3708234 | 0.81 | KDM4E (0.47) | ALDH1A1KDM4EHPGDLMNA | |
| SCHEMBL16254979 | 0.77 | CNR1 (0.47) | ALDH1A1KDM4EHPGDSMN1; SMN2MAPK1 | |
| SCHEMBL8466470 | 0.73 | HPGD (0.54) | ALDH1A1HPGDSMN1; SMN2LMNAMAPK1 | |
| SCHEMBL12224346 | 0.73 | HPGD (0.54) | ALDH1A1HPGDSMN1; SMN2LMNAMAPK1 | |
| SCHEMBL8459065 | 0.73 | HPGD (0.54) | ALDH1A1HPGDSMN1; SMN2LMNAMAPK1 | |
| SCHEMBL4256387 | 0.73 | HPGD (0.54) | ALDH1A1HPGDSMN1; SMN2LMNAMAPK1 | |
| SCHEMBL13674774 | 0.73 | HPGD (0.54) | ALDH1A1HPGDSMN1; SMN2LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889670-B2 | Heterocyclic compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ALDH1A1 2533/4885KDM4E 2973/4885CYP3A4 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.